Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.45 |
| ▸ | SCN2B | O60939 | 2/20 | 0.43 |
| ▸ | SCN1A | P35498 | 2/20 | 0.43 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680209 | 0.89 | SCN9A (0.48) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL680555 | 0.88 | SLC22A12 (0.50) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL679146 | 0.87 | SCN9A (0.52) | SCN9ASCN5ASCN3APLA2G7EZH2 | |
| SCHEMBL679923 | 0.86 | SCN3A (0.47) | SCN9ASCN5ASCN3A | |
| SCHEMBL679345 | 0.85 | SCN9A (0.51) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL680832 | 0.84 | PLA2G7 (0.55) | SCN9ASCN5APLA2G7EZH2 | |
| SCHEMBL680538 | 0.83 | SCN9A (0.53) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL679917 | 0.83 | SCN9A (0.50) | SCN9ASCN5APLA2G7 | |
| SCHEMBL680375 | 0.82 | SCN9A (0.50) | SCN9ASCN5APLA2G7EZH2 | |
| SCHEMBL16319332 | 0.82 | SCN9A (0.61) | SCN9ASCN5APLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | TBXA2R 577/4885AR 392/4885SCN9A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.